GlobeNewswire·Apr 20, 2026, 8:30 AM ET

CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026

CytoDyn Inc. presented new clinical and translational data on leronlimab for metastatic triple-negative breast cancer (mTNBC) at the AACR Annual Meeting 2026 in San Diego.
Leronlimab, a CCR5 inhibitor, modulates immune checkpoint signaling & induces PD-L1 expression in mTNBC patients.
CCR5 expression correlates with T-cell immune exhaustion & is enriched in mesenchymal-like immune-altered (MLIA) & immunomodulatory (IM) TNBC subtypes.
Preclinical models show leronlimab increases PD-L1 expression while attenuating resistance mediators sB7-H3 & Tyro3 signaling.
Retrospective analysis of 28 heavily pretreated mTNBC patients revealed leronlimab induced PD-L1 in circulating tumor cells & cancer-associated macrophage-like cells.
Higher leronlimab doses, PD-L1 induction, & use with or after immune checkpoint inhibitors (ICIs) correlated with improved survival outcomes.
17.9% (5 out of 28) of heavily pretreated patients remained alive after more than 60 months of follow-up.
Dr. Richard G. Pestell is the first author of the presentation titled "Leronlimab induces PD-L1 expression and is associated with long term survival with an ICI in PD-L1 low metastatic TNBC" (Poster #1033).